Howard L. Levine Elected to Board of Protein Sciences, Swine Flu Vaccine Developer
Howard L. Levine, Ph.D., President of BioProcess Technology Consultants, Inc., has been elected to the Board of Directors of Protein Sciences Corporation, developer of FluBlok® seasonal influenza vaccine and PanBlok® vaccine for the new H1N1 swine flu and other potential pandemic influenza viruses.
Dr. Levine is an international expert in biologics development and manufacturing and provides strategic, technical, and regulatory consulting services to biopharmaceutical companies to help accelerate the development and commercialization of new biopharmaceutical products.
“Dr. Levine’s expertise in cell culture scale-up, plus his knowledge and experience with flu vaccine manufacturing make him a valuable addition as we rapidly scale up to be able to manufacture PanBlok vaccine for the potential swine flu pandemic by early to mid-June,” said Daniel D. Adams, Protein Sciences President, CEO, and newly elected Chairman of the Board of Directors. The company expects its FluBlok vaccine to receive FDA approval in 2009.
Before founding BioProcess Technology Consultants, Dr. Levine was Vice President of Manufacturing Operations at Repligen Corporation, and has held positions in process development and manufacturing at Genentech, Amgen, and Xoma. He is a member of the Editorial Advisory Boards of BioPharm Magazine and Bio/Pharmaceutical Outsourcing Report and is on the Advisory Boards of Acretia Inc., and Nexbio, Inc. He holds a Ph.D. in chemistry from the University of Chicago and completed a post-doctoral fellowship at Harvard University.
“Protein Sciences’ innovative protein expression technology shows great promise in battling the new strain of swine flu,” said Dr. Levine. “I’m pleased to join their Board at this pivotal time.”
About BioProcess Technology Consultants, Inc.
Founded in 1994, BioProcess Technology Consultants provides a full range of technical, business, and operations assistance to pharmaceutical and biotechnology companies in the development and commercialization of new biopharmaceutical products. The company specializes in helping clients to develop manufacturing processes and strategies and assists in developing product discovery and process development programs that help speed products from clone to commercial.®BioProcess Technology Consultants also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more about BioProcess Technology Consultants, visit http://www.bptc.com. For information on Protein Sciences Corporation, go to http://www.proteinsciences.com.